Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Blockade of the kallikrein-kinin system reduces endothelial complement activation in vascular inflammation.

Lopatko Fagerström I, Ståhl AL, Mossberg M, Tati R, Kristoffersson AC, Kahn R, Bascands JL, Klein J, Schanstra JP, Segelmark M, Karpman D.

EBioMedicine. 2019 Aug 20. pii: S2352-3964(19)30542-0. doi: 10.1016/j.ebiom.2019.08.020. [Epub ahead of print]

2.
3.

Clinical and Complement Long-Term Follow-Up of a Pediatric Patient with C3 Mutation-Related Atypical Hemolytic Uremic Syndrome.

Bjerre A, Bergseth G, Ludviksen JK, Stokke A, Bosnes V, Karpman D, Mollnes TE.

Case Rep Nephrol. 2018 Dec 18;2018:3810249. doi: 10.1155/2018/3810249. eCollection 2018.

4.

Aliskiren inhibits renin-mediated complement activation.

Békássy ZD, Kristoffersson AC, Rebetz J, Tati R, Olin AI, Karpman D.

Kidney Int. 2018 Oct;94(4):689-700. doi: 10.1016/j.kint.2018.04.004. Epub 2018 Jun 5.

PMID:
29884545
5.

Exosomes and microvesicles in normal physiology, pathophysiology, and renal diseases.

Ståhl AL, Johansson K, Mossberg M, Kahn R, Karpman D.

Pediatr Nephrol. 2019 Jan;34(1):11-30. doi: 10.1007/s00467-017-3816-z. Epub 2017 Nov 27. Review.

6.

Microvesicle Involvement in Shiga Toxin-Associated Infection.

Villysson A, Tontanahal A, Karpman D.

Toxins (Basel). 2017 Nov 19;9(11). pii: E376. doi: 10.3390/toxins9110376. Review.

7.

Extracellular vesicles in renal disease.

Karpman D, Ståhl AL, Arvidsson I.

Nat Rev Nephrol. 2017 Sep;13(9):545-562. doi: 10.1038/nrneph.2017.98. Epub 2017 Jul 24. Review.

PMID:
28736435
8.

C1-Inhibitor Decreases the Release of Vasculitis-Like Chemotactic Endothelial Microvesicles.

Mossberg M, Ståhl AL, Kahn R, Kristoffersson AC, Tati R, Heijl C, Segelmark M, Leeb-Lundberg LMF, Karpman D.

J Am Soc Nephrol. 2017 Aug;28(8):2472-2481. doi: 10.1681/ASN.2016060637. Epub 2017 Mar 13.

9.

Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis.

Brackman D, Sartz L, Leh S, Kristoffersson AC, Bjerre A, Tati R, Frémeaux-Bacchi V, Karpman D.

Nephrol Dial Transplant. 2017 Mar 1;32(3):584. doi: 10.1093/ndt/gfx013. No abstract available.

PMID:
28168280
10.

Neutrophil Protease Cleavage of Von Willebrand Factor in Glomeruli - An Anti-thrombotic Mechanism in the Kidney.

Tati R, Kristoffersson AC, Manea Hedström M, Mörgelin M, Wieslander J, van Kooten C, Karpman D.

EBioMedicine. 2017 Feb;16:302-311. doi: 10.1016/j.ebiom.2017.01.032. Epub 2017 Jan 24.

11.

Microvesicle transfer of kinin B1-receptors is a novel inflammatory mechanism in vasculitis.

Kahn R, Mossberg M, Ståhl AL, Johansson K, Lopatko Lindman I, Heijl C, Segelmark M, Mörgelin M, Leeb-Lundberg LM, Karpman D.

Kidney Int. 2017 Jan;91(1):96-105. doi: 10.1016/j.kint.2016.09.023. Epub 2016 Dec 1.

PMID:
27914700
12.

Orphan drug policies and use in pediatric nephrology.

Karpman D, Höglund P.

Pediatr Nephrol. 2017 Jan;32(1):1-6. Epub 2016 Oct 13.

PMID:
27738765
13.

Haemolytic uraemic syndrome.

Karpman D, Loos S, Tati R, Arvidsson I.

J Intern Med. 2017 Feb;281(2):123-148. doi: 10.1111/joim.12546. Epub 2016 Oct 10. Review.

14.

Complement contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome.

Karpman D, Tati R.

Kidney Int. 2016 Oct;90(4):726-9. doi: 10.1016/j.kint.2016.07.002.

PMID:
27633864
15.

Early Terminal Complement Blockade and C6 Deficiency Are Protective in Enterohemorrhagic Escherichia coli-Infected Mice.

Arvidsson I, Rebetz J, Loos S, Herthelius M, Kristoffersson AC, Englund E, Chromek M, Karpman D.

J Immunol. 2016 Aug 15;197(4):1276-86. doi: 10.4049/jimmunol.1502377. Epub 2016 Jul 15.

16.

Complement Interactions with Blood Cells, Endothelial Cells and Microvesicles in Thrombotic and Inflammatory Conditions.

Karpman D, Ståhl AL, Arvidsson I, Johansson K, Loos S, Tati R, Békássy Z, Kristoffersson AC, Mossberg M, Kahn R.

Adv Exp Med Biol. 2015;865:19-42. doi: 10.1007/978-3-319-18603-0_2. Review.

PMID:
26306441
17.

Enterohemorrhagic Escherichia coli Pathogenesis and the Host Response.

Karpman D, Ståhl AL.

Microbiol Spectr. 2014 Oct;2(5). doi: 10.1128/microbiolspec.EHEC-0009-2013. Review.

PMID:
26104359
18.

[The council for new therapies should immediately revoke their decision on eculizumab].

Karpman D, Fehrman-Ekholm I, Bárány P, Békássy Z, Brandström P, Bruchfeld A, Celsi G, Chromek M, Clyne N, Fellström B, Hansson S, Haraldsson B, Nevéus T, Rippe B, Sartz L, Segelmark M, Stegmayr B, Stenvinkel P, Westman K.

Lakartidningen. 2015 Jun 11;112. pii: DI7D. Swedish. No abstract available.

19.

[The council for new therapies position on eculizumab is unacceptable].

Karpman D, Fehrman-Ekholm I, Bárány P, Békássy Z, Brandström P, Bruchfeld A, Celsi G, Chromek M, Clyne N, Fellström B, Hansson S, Haraldsson B, Nevéus T, Rippe B, Sartz L, Segelmark M, Stegmayr B, Stenvinkel P, Tufveson G, Westman K.

Lakartidningen. 2015 Jun 9;112. pii: DI3F. Swedish. No abstract available.

20.

An international consensus approach to the management of atypical hemolytic uremic syndrome in children.

Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Frémeaux-Bacchi V; HUS International.

Pediatr Nephrol. 2016 Jan;31(1):15-39. doi: 10.1007/s00467-015-3076-8. Epub 2015 Apr 11. Review.

PMID:
25859752
21.

A novel mechanism of bacterial toxin transfer within host blood cell-derived microvesicles.

Ståhl AL, Arvidsson I, Johansson KE, Chromek M, Rebetz J, Loos S, Kristoffersson AC, Békássy ZD, Mörgelin M, Karpman D.

PLoS Pathog. 2015 Feb 26;11(2):e1004619. doi: 10.1371/journal.ppat.1004619. eCollection 2015 Feb.

22.

Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome.

Arvidsson I, Ståhl AL, Hedström MM, Kristoffersson AC, Rylander C, Westman JS, Storry JR, Olsson ML, Karpman D.

J Immunol. 2015 Mar 1;194(5):2309-18. doi: 10.4049/jimmunol.1402470. Epub 2015 Jan 30.

23.

Eculizumab treatment for rescue of renal function in IgA nephropathy.

Rosenblad T, Rebetz J, Johansson M, Békássy Z, Sartz L, Karpman D.

Pediatr Nephrol. 2014 Nov;29(11):2225-8. doi: 10.1007/s00467-014-2863-y. Epub 2014 Jun 13.

PMID:
24924752
24.

The combined role of galactose-deficient IgA1 and streptococcal IgA-binding M Protein in inducing IL-6 and C3 secretion from human mesangial cells: implications for IgA nephropathy.

Schmitt R, Ståhl AL, Olin AI, Kristoffersson AC, Rebetz J, Novak J, Lindahl G, Karpman D.

J Immunol. 2014 Jul 1;193(1):317-26. doi: 10.4049/jimmunol.1302249. Epub 2014 May 21.

25.

An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome.

Johnson S, Stojanovic J, Ariceta G, Bitzan M, Besbas N, Frieling M, Karpman D, Landau D, Langman C, Licht C, Pecoraro C, Riedl M, Siomou E, van de Kar N, Walle JV, Loirat C, Taylor CM.

Pediatr Nephrol. 2014 Oct;29(10):1967-78. doi: 10.1007/s00467-014-2817-4. Epub 2014 May 11.

PMID:
24817340
26.

[23 physicians comments on circumcision of small boys: The Swedish Medical Association should take a more humble approach].

Altman M, Altman D, Fischler B, Björkstén B, Bruchfeld A, Böhm F, Chrapkowska C, Finder M, Finkel Y, Halmin M, Heyman M, Ilicki A, Kahn R, Karpman D, Katz-Salamon M, Lagercrantz H, Mårtensson T, Nisell H, Rosling H, Sarman I, Wackernagel D, Wennergren G, Wilczek M.

Lakartidningen. 2014 Mar 12-18;111(11):494-5. Swedish. No abstract available.

PMID:
24720027
27.

Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions.

Békássy ZD, Kristoffersson AC, Cronqvist M, Roumenina LT, Rybkine T, Vergoz L, Hue C, Fremeaux-Bacchi V, Karpman D.

Nephrol Dial Transplant. 2013 Nov;28(11):2899-907. doi: 10.1093/ndt/gft340. Epub 2013 Sep 5.

PMID:
24009284
28.

Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy.

Tati R, Kristoffersson AC, Ståhl AL, Rebetz J, Wang L, Licht C, Motto D, Karpman D.

J Immunol. 2013 Sep 1;191(5):2184-93. doi: 10.4049/jimmunol.1301221. Epub 2013 Jul 22. Erratum in: J Immunol. 2014 Feb 15;192(4):1990.

29.

Ouabain protects against Shiga toxin-triggered apoptosis by reversing the imbalance between Bax and Bcl-xL.

Burlaka I, Liu XL, Rebetz J, Arvidsson I, Yang L, Brismar H, Karpman D, Aperia A.

J Am Soc Nephrol. 2013 Sep;24(9):1413-23. doi: 10.1681/ASN.2012101044. Epub 2013 Jun 6.

30.

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C.

N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981.

31.

Complement activation in thrombotic microangiopathy.

Karpman D, Tati R.

Hamostaseologie. 2013 May 29;33(2):96-104. doi: 10.5482/HAMO-12-12-0025. Epub 2013 Feb 15. Review.

PMID:
23411690
32.

Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed.

Karpman D.

Nephrol Dial Transplant. 2012 Oct;27(10):3669-74. doi: 10.1093/ndt/gfs456. No abstract available.

33.

The antimicrobial peptide cathelicidin protects mice from Escherichia coli O157:H7-mediated disease.

Chromek M, Arvidsson I, Karpman D.

PLoS One. 2012;7(10):e46476. doi: 10.1371/journal.pone.0046476. Epub 2012 Oct 15.

34.

Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab.

Besbas N, Gulhan B, Karpman D, Topaloglu R, Duzova A, Korkmaz E, Ozaltin F.

Pediatr Nephrol. 2013 Jan;28(1):155-8. doi: 10.1007/s00467-012-2296-4. Epub 2012 Sep 6.

PMID:
22956028
35.

Editorial commentary: Escherichia coli O104:H4 and hemolytic uremic syndrome: the analysis begins.

Tarr PI, Karpman D.

Clin Infect Dis. 2012 Sep;55(6):760-3. doi: 10.1093/cid/cis533. Epub 2012 Jun 5. No abstract available.

PMID:
22670035
36.

A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome.

Sartz L, Olin AI, Kristoffersson AC, Ståhl AL, Johansson ME, Westman K, Fremeaux-Bacchi V, Nilsson-Ekdahl K, Karpman D.

J Immunol. 2012 Feb 15;188(4):2030-7. doi: 10.4049/jimmunol.1100319. Epub 2012 Jan 16.

37.

Shiga toxin pathogenesis: kidney complications and renal failure.

Obrig TG, Karpman D.

Curr Top Microbiol Immunol. 2012;357:105-36. doi: 10.1007/82_2011_172. Review.

38.

Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis.

Brackman D, Sartz L, Leh S, Kristoffersson AC, Bjerre A, Tati R, Frémeaux-Bacchi V, Karpman D.

Nephrol Dial Transplant. 2011 Oct;26(10):3399-403. doi: 10.1093/ndt/gfr422. Epub 2011 Aug 1. Erratum in: Nephrol Dial Transplant. 2017 Mar 1;32(3):584.

PMID:
21810760
39.

Phenotypic expression of ADAMTS13 in glomerular endothelial cells.

Tati R, Kristoffersson AC, Ståhl AL, Mörgelin M, Motto D, Satchell S, Mathieson P, Manea-Hedström M, Karpman D.

PLoS One. 2011;6(6):e21587. doi: 10.1371/journal.pone.0021587. Epub 2011 Jun 24.

40.

Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome.

Ståhl AL, Sartz L, Karpman D.

Blood. 2011 May 19;117(20):5503-13. doi: 10.1182/blood-2010-09-309161. Epub 2011 Mar 29.

41.

Cross-reactive protection against enterohemorrhagic Escherichia coli infection by enteropathogenic E. coli in a mouse model.

Calderon Toledo C, Arvidsson I, Karpman D.

Infect Immun. 2011 Jun;79(6):2224-33. doi: 10.1128/IAI.01024-10. Epub 2011 Mar 14.

42.

Kinin system activation in vasculitis.

Kahn R, Karpman D.

Acta Paediatr. 2011 Jul;100(7):950-7. doi: 10.1111/j.1651-2227.2011.02266.x. Epub 2011 Apr 8. Review.

PMID:
21401717
43.

Hyperfiltration evaluated by glomerular filtration rate at diagnosis in children with cancer.

Hjorth L, Wiebe T, Karpman D.

Pediatr Blood Cancer. 2011 May;56(5):762-6. doi: 10.1002/pbc.22971. Epub 2011 Jan 16.

PMID:
21370408
44.

Successful management of a planned pregnancy in severe congenital thrombotic thrombocytopaenic purpura: the Upshaw-Schulman syndrome.

Richter J, Strandberg K, Lindblom A, Strevens H, Karpman D, Wide-Swensson D.

Transfus Med. 2011 Jun;21(3):211-3. doi: 10.1111/j.1365-3148.2010.01067.x. Epub 2011 Jan 11. No abstract available.

PMID:
21219489
45.

Pathogen specific, IRF3-dependent signaling and innate resistance to human kidney infection.

Fischer H, Lutay N, Ragnarsdóttir B, Yadav M, Jönsson K, Urbano A, Al Hadad A, Rämisch S, Storm P, Dobrindt U, Salvador E, Karpman D, Jodal U, Svanborg C.

PLoS Pathog. 2010 Sep 23;6(9):e1001109. doi: 10.1371/journal.ppat.1001109.

46.

Pathophysiology of typical hemolytic uremic syndrome.

Karpman D, Sartz L, Johnson S.

Semin Thromb Hemost. 2010 Sep;36(6):575-85. doi: 10.1055/s-0030-1262879. Epub 2010 Sep 23. Review.

PMID:
20865634
47.

Intestinal damage in enterohemorrhagic Escherichia coli infection.

Békássy ZD, Calderon Toledo C, Leoj G, Kristoffersson A, Leopold SR, Perez MT, Karpman D.

Pediatr Nephrol. 2011 Nov;26(11):2059-71. doi: 10.1007/s00467-010-1616-9. Epub 2010 Sep 1.

PMID:
20809220
48.

IgA nephropathy associated with a novel N-terminal mutation in factor H.

Schmitt R, Krmar RT, Kristoffersson A, Söderberg M, Karpman D.

Eur J Pediatr. 2011 Jan;170(1):107-10. doi: 10.1007/s00431-010-1279-3. Epub 2010 Aug 24.

PMID:
20734203
49.

Antibody response to IgA-binding streptococcal M proteins in children with IgA nephropathy.

Schmitt R, Lindahl G, Karpman D.

Nephrol Dial Transplant. 2010 Oct;25(10):3434-6. doi: 10.1093/ndt/gfq346. Epub 2010 Jun 17.

PMID:
20558662
50.

Toll-like receptor 4 promoter polymorphisms: common TLR4 variants may protect against severe urinary tract infection.

Ragnarsdóttir B, Jönsson K, Urbano A, Grönberg-Hernandez J, Lutay N, Tammi M, Gustafsson M, Lundstedt AC, Leijonhufvud I, Karpman D, Wullt B, Truedsson L, Jodal U, Andersson B, Svanborg C.

PLoS One. 2010 May 20;5(5):e10734. doi: 10.1371/journal.pone.0010734.

Supplemental Content

Loading ...
Support Center